Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.

Human molecular genetics - 13 Jan 2023

Harlow Charli E, Patel Vickas V, Waterworth Dawn M, Wood Andrew R, Beaumont Robin N, Ruth Katherine S, Tyrrell Jessica, Oguro-Ando Asami, Chu Audrey Y, Frayling Timothy M

Abstract excerpt

Prolyl hydroxylase (PHD) inhibitors are in clinical development for anaemia in chronic kidney disease. Epidemiological studies have reported conflicting results regarding safety of long-term therapeutic haemoglobin (Hgb) rises through PHD inhibition on risk of cardiovascular disease. Genetic variation in genes encoding PHDs can be used as partial proxies to investigate the potential effects of long-term Hgb...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Heart Disease Risk Factors

Share to Mendelian Randomization Analysis

Share to Risk Factors

Share to Stroke

Source

Open in PubMed Open full text

Identifiers

PMID: 36048866
DOI: 10.1093/hmg/ddac215
PMCID: PMC9851745

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.PMID 36048866Read ↗

Genetically proxied inhibition of angiotensinogen synthesis is associated with lower cardiovascular riskSemantic proximity Read ↗

Genetically proxied inhibition of L-2-hydroxyglutarate dehydrogenase and the risk of coronary artery disease: A Mendelian randomization studySemantic proximity Read ↗

Estimating the Population Benefits of Blood Pressure Lowering: A Wide-Angled Mendelian Randomization Study in UK BiobankSemantic proximity Read ↗

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.Semantic proximity Read ↗

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancersSemantic proximity Read ↗

Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.Semantic proximity Read ↗

Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization studySemantic proximity Read ↗

Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal HematopoiesisSemantic proximity Read ↗

Triangulating Evidence for Antihypertensive Drug Class Efficacy on Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and ColocalisationSemantic proximity Read ↗

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read ↗

A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes.Semantic proximity Read ↗

Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach in management of Anemia of Chronic Kidney DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.